Quick Summary — DBVT scores higher on quality with 4.9/10 vs BNTX's 1.7/10. BNTX trades at $89.14 while DBVT trades at $18.23. Both analyzed daily using SEC EDGAR data across 13 institutional models.
DBVT scores higher with a 4.9/10 quality rating vs BNTX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $89.14, BNTX trades +66.9% above its Bayesian DCF fair value of $29.53, while DBVT at $18.23 trades +62.4% above its estimate of $6.85. BNTX shows a wider gap between price and intrinsic value.
BNTX earns a Quality of Company score of 1.7/10 compared to DBVT's 4.9/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both BNTX and DBVT to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both BNTX and DBVT operate in Biological Products, (No Diagnostic Substances), which has 6 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare BNTX vs DBVT differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.